Clinical Context & Research Overview Important: Peptide therapy for performance and sleep support should be discussed with a licensed clinician
If you are focused on general maintenance, your needs will look different than someone focused on targeted cellular support or recovery

Ipamorelin Receptor: GHS-R1a | Half-life: ~2 hrs | GH potency: Moderate | Selectivity: High (no cortisol/prolactin) | Appetite effect: Minimal GHRP-6 Receptor: GHS-R1a | Half-life: ~20 min | GH potency: High | Selectivity: Low (elevates cortisol, prolactin, appetite) | Appetite effect: Strong GHRP-2 Receptor: GHS-R1a | Half-life: ~25 min | GH potency: High | Selectivity: Moderate (mild cortisol elevation) | Appetite effect: Moderate Hexarelin Receptor: GHS-R1a | Half-life: ~30 min | GH potency: Highest | Selectivity: Lowest (significant cortisol/prolactin) | Appetite effect: Moderate CJC-1295 no-DAC Receptor: GHRH-R | Half-life: ~30 min | GH potency: Moderate | Selectivity: High (GHRH-pathway only) | Appetite effect: None CJC-1295 DAC Receptor: GHRH-R | Half-life: ~6-8 days | GH potency: Sustained moderate | Selectivity: High | Appetite effect: None Sermorelin Receptor: GHRH-R | Half-life: ~10-20 min | GH potency: Moderate | Selectivity: High | Appetite effect: None Analytical Verification of GHS Peptides Growth hormone secretagogues are among the most frequently counterfeited or under-dosed peptides in the research market due to their popularity and relatively high cost of synthesis

Nov 19, 2025: Updated all Shed pricing, including revised ranges for both brand-name and compounded medications
GLP-1 is an abbreviation for Glucagon-Like Peptide-1 receptor agonist, which is a class of medications commonly used to treat diabetes and to assist with weight loss in patients with or without diabetes
doi: 10.1038/s41591-025-03799-0 48